ClinicalTrials.gg

Program

penpulimab

Also written as “AK105”, “Penpulimab” and “Penpulimab injection”.

Its studies are mostly in Carcinoma, Hepatocellular · Nasopharyngeal Carcinoma · Carcinoma, Non-Small-Cell Lung · Hodgkin Disease · Esophageal Squamous Cell Carcinoma, led by 2 companies.

Furthest: phase 3, since Apr 10, 202027 company-led studies, 9 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical187 open or runningphase 3since Apr 10, 2020Dec 17, 2019Dec 2026phase 3 · NCT04344158
Akeso92 open or runningphase 3since Mar 6, 2019Nov 21, 2017none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 12 studies since Nov 21, 2017.

  1. Jul 13, 2021Phase 3 study in Nasopharyngeal CarcinomaAkeso · NCT04974398 · 296 enrolled · United States, Australia, Brazil and more
  2. Sep 24, 2021Phase 2 study in Unresectable Metastatic Colorectal CancerSino Biopharmaceutical · NCT05068206 · 120 enrolled · China
  3. Jan 25, 2022Phase 3 study in Hodgkin Disease LymphomaAkeso · NCT05244642 · 60 planned · China
  4. Apr 12, 2022Phase 1 study in Advanced CancersSino Biopharmaceutical · NCT05333276 · 7 enrolled · China
  5. May 16, 2022Phase 2 study in LymphomaSino Biopharmaceutical · NCT05400876 · 92 enrolled · China
  6. Sep 27, 2022Phase 2 study in Nasopharyngeal CarcinomaSino Biopharmaceutical · NCT05563480 · 47 enrolled · China
  7. Apr 18, 2023Phase 2 study in Advanced Esophageal Squamous Cell CarcinomaSino Biopharmaceutical · NCT05834543 · 34 enrolled · China
  8. May 15, 2023Phase 3 study in Carcinoma, HepatocellularSino Biopharmaceutical · NCT05862337 · 480 planned · China
  9. May 31, 2023Phase 1 study in Advanced CancerSino Biopharmaceutical · NCT05894421 · 92 planned · China
  10. Jul 27, 2023Phase 1 study in Advanced Hepatocellular CarcinomaSino Biopharmaceutical · NCT05975645 · 29 enrolled · China
  11. Mar 1, 20242 phase 1 studiesSino Biopharmaceutical · NCT06297642, NCT06320080
  12. Jul 8, 2024Phase 2 study in SarcomaSino Biopharmaceutical · NCT06500091 · 54 planned · China
  13. Jan 6, 2025Phase 2 study in Gastroesophageal AdenocarcinomaSino Biopharmaceutical · NCT06767800 · 204 planned · China
  14. Feb 9, 2025Phase 2 study in Advanced Solid TumorSino Biopharmaceutical · NCT06825494 · 194 planned · China

Ahead

  1. Dec 2026Primary completion: phase 3 study in Advanced Hepatocellular Carcinoma (HCC)Sino Biopharmaceutical · NCT04344158

TargetBeta

PDCD1 →read by rule
“A monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), ”NCIt, by rule
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

All 27 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06825494Advanced Solid Tumor · China2RecruitingSino BiopharmaceuticalMar 2026194
NCT06767800Gastroesophageal Adenocarcinoma · China2RecruitingSino BiopharmaceuticalSep 2026204
NCT06500091Sarcoma · China2Not yet recruitingSino BiopharmaceuticalJun 202654
NCT06320080Advanced Hepatocellular Carcinoma · China1TerminatedSino BiopharmaceuticalNov 3, 202522
NCT06297642Advanced Malignant Neoplasm · China1TerminatedSino BiopharmaceuticalJul 31, 20243
NCT05975645Advanced Hepatocellular Carcinoma · China1TerminatedSino BiopharmaceuticalJun 4, 202529
NCT05894421Advanced Cancer · China1RecruitingSino BiopharmaceuticalJan 202592
NCT05862337Carcinoma, Hepatocellular · China3RecruitingSino BiopharmaceuticalAug 2024480
NCT05834543Advanced Esophageal Squamous Cell Carcinoma · China2TerminatedSino BiopharmaceuticalOct 23, 202434
NCT05563480Nasopharyngeal Carcinoma · China2CompletedSino BiopharmaceuticalMay 28, 202547
NCT05400876Lymphoma · China2UNKNOWNSino BiopharmaceuticalMay 202392
NCT05333276Advanced Cancers · China1Active, not recruitingSino BiopharmaceuticalDec 20237
NCT05244642Hodgkin Disease Lymphoma · China3RecruitingAkesoDec 30, 202560
NCT05068206Unresectable Metastatic Colorectal Cancer · China2UNKNOWNSino BiopharmaceuticalDec 2023120
NCT04974398Nasopharyngeal Carcinoma · United States, Australia, Brazil and more3Active, not recruitingAkesoFeb 23, 2026296
NCT04385550Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma · China3UNKNOWNSino BiopharmaceuticalOct 31, 2023528
NCT04344158Advanced Hepatocellular Carcinoma (HCC) · China3Active, not recruitingSino BiopharmaceuticalDec 2026648
NCT04291248MSI-H or dMMR Advanced Solid Tumors · China2UNKNOWNSino BiopharmaceuticalDec 2022138
NCT04207463Digestive System Neoplasms · China2UNKNOWNSino BiopharmaceuticalDec 31, 2020150
NCT04203719Advanced Head, Neck and Chest Cancer · China2UNKNOWNSino BiopharmaceuticalDec 31, 2020140
NCT04172571Carcinoma, Hepatocellular · China2CompletedAkesoJun 1, 202231
NCT04172506Lung Neoplasms · China2CompletedAkesoDec 1, 202165
NCT03866993Carcinoma, Non-Small-Cell Lung · China3CompletedAkesoOct 8, 2020350
NCT03866980Carcinoma, Non-Small-Cell Lung · China3TerminatedAkesoJun 30, 2023164
NCT03866967Nasopharyngeal Carcinoma · China2CompletedAkesoMar 13, 2021130
NCT03722147Hodgkin Disease · China2CompletedAkesoJan 10, 202094
NCT03352531Advanced Cancer · Australia1CompletedAkesoNov 30, 202099

How it is read

Names in the registry

  • “AK105”, 9 entries
  • “Penpulimab”, 3 entries
  • “Penpulimab injection”, 2 entries
  • “AK105 injection”, 2 entries
  • “TQB2618 injection; Penpulimab injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.